Great Novel Therapeutics Biotech & Medicals (ROCO:7427) EV-to-FCF : -10.62 (As of Sep. 20, 2024)

Great Novel Therapeutics Biotech & Medicals EV-to-FCF Chart

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EV-to-FCF	Get a 7-Day Free Trial						-	-20.13	-	-28.30	-

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's EV-to-FCF

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's EV-to-FCF falls into.

Great Novel Therapeutics Biotech & Medicals EV-to-FCF Calculation

Great Novel Therapeutics Biotech & Medicals's EV-to-FCF for today is calculated as:

Great Novel Therapeutics Biotech & Medicals's current Enterprise Value is NT$959.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Great Novel Therapeutics Biotech & Medicals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-90.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Great Novel Therapeutics Biotech & Medicals's PE Ratio for today is calculated as:

Great Novel Therapeutics Biotech & Medicals's share price for today is NT$35.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Great Novel Therapeutics Biotech & Medicals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-2.195.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Great Novel Therapeutics Biotech & Medicals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals Business Description